Boehringer Ingelheim and Autigen Collaborate to Discover and Develop Novel Treatments for Hearing Loss
Shots:
- Autigen to receive upfront & research funding and is eligible for up to $100M, if all the milestones are achieved during the partnership, along with royalties on products that emerges from the collaboration
- Boehringer Ingelheim will be responsible for further preclinical and clinical development, and commercialization of transformative therapies for patients with SNHL
- The collaboration will advance Autigen’s leadership in novel therapies for SHNL and marks the first partnership of Autigen out of the pharmaceutical accelerator, Ascend BioVentures
Ref: Businesswire | Image: Boehringer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.